The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia

American Journal of Reproductive Immunology

Volumn 75, Issue 2, 2016, Pages 104-111

  Lynch, Anne M ^a   Wagner, Brandie D ^b   Giclas, Patricia C ^c   West, Nancy A ^b   Gibbs, Ronald S ^a   Holers, V Michael ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Food Science and Human Nutrition   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

Author keywords

Complement Bb; Gestational age; Preeclampsia

Indexed keywords

COMPLEMENT; COMPLEMENT BB; UNCLASSIFIED DRUG; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNOREGULATION; PREECLAMPSIA; PRIORITY JOURNAL; BLOOD; CASE CONTROL STUDY; PRE-ECLAMPSIA; PREGNANCY; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; COMPLEMENT FACTOR B; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; YOUNG ADULT;

EID: 84956714378     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12439     Document Type: Article

References (36)

1. Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet 2005; 365:785-799.
2. Zhang J, Meikle S, Trumble A: Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 2003; 22:203-212.
3. Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, Salmon JE, Holers VM: Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008; 198:385 e1-9.
4. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ: Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160:1405-1423.
5. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
6. Moffett A, Hiby SE: How does the maternal immune system contribute to the development of pre-eclampsia? Placenta 2007; 28(Suppl A):S51-S56.
7. Redman CW, Sacks GP, Sargent IL: Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180(Pt 1):499-506.
8. Lynch AM, Salmon JE: Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 2010; 31:561-567.
9. Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, Holers VM: The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010; 117:456-462.
10. Lynch AM, Eckel RH, Murphy JR, Gibbs RS, West NA, Giclas PC, Salmon JE, Holers VM: Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol 2012; 206:428 e1-8.
11. Derzsy Z, Prohaszka Z, Rigo J Jr, Fust G, Molvarec A: Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010; 47:1500-1506.
12. Abramson SB, Buyon JP: Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Am J Reprod Immunol 1992; 28:183-187.
13. Haeger M: The role of complement in pregnancy-induced hypertensive disease. Int J Gynaecol Obstet 1993; 43:113-127.
14. Denny KJ, Coulthard LG, Finnell RH, Callaway LK, Taylor SM, Woodruff TM: Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. J Reprod Immunol 2013; 97:211-216.
15. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP: Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011; 8:e1001013.
16. Hoffman MC, Rumer KK, Kramer A, Lynch AM, Winn VD: Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol 2014; 71:55-60.
17. Soto E, Romero R, Richani K, Espinoza J, Chaiworapongsa T, Nien JK, Edwin SS, Kim YM, Hong JS, Goncalves LF, Yeo L, Mazor M, Hassan SS, Kusanovic JP: Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med 2010; 23:646-657.
18. Rampersad R, Barton A, Sadovsky Y, Nelson DM: The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta 2008; 29:855-861.
19. Buurma A, Cohen D, Veraar K, Schonkeren D, Claas FH, Bruijn JA, Bloemenkamp KW, Baelde HJ: Preeclampsia is characterized by placental complement dysregulation. Hypertension 2012; 60:1332-1337.
20. Lillegard KE, Johnson AC, Lojovich SJ, Bauer AJ, Marsh HC, Gilbert JS, Regal JF: Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol 2013; 56:91-97.
21. Holers VM: Complement and its receptors: new insights into human disease. Annu Rev Immunol 2014; 32:433-459.
22. Markiewski MM, Lambris JD: The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007; 171:715-727.
23. Sjoberg AP, Trouw LA, Blom AM: Complement activation and inhibition: a delicate balance. Trends Immunol 2009; 30:83-90.
24. Holers VM: The complement system as a therapeutic target in autoimmunity. Clin Immunol 2003; 107:140-151.
25. Thurman JM, Holers VM: The central role of the alternative complement pathway in human disease. J Immunol 2006; 176:1305-1310.
26. Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-797.
27. Noris M, Remuzzi G: Overview of complement activation and regulation. Semin Nephrol 2013; 33:479-492.
28. Zipfel PF, Heinen S, Jozsi M, Skerka C: Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006; 43:97-106.
29. Zipfel PF, Skerka C: Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729-740.
30. Catalano PM: Management of obesity in pregnancy. Obstet Gynecol 2007; 109(Pt 1):419-433.
31. Cleveland WS, Grosse E: Computational methods for local regression. Stat Comput 1991; 1:47-62.
32. Mor G, Cardenas I, Abrahams V, Guller S: Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci 2011; 1221:80-87.
33. Bulla R, Bossi F, Fischetti F, De Seta F, Tedesco F: The complement system at the fetomaternal interface. Chem Immunol Allergy 2005; 89:149-157.
34. Burton GJ, Watson AL, Hempstock J, Skepper JN, Jauniaux E: Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. J Clin Endocrinol Metab 2002; 87:2954-2959.
35. Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM: Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol 2011; 117:75-83.
36. Holers VM, Thurman JM: The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol 2004; 41:147-152.